AbbVie’s Rinvoq yields positive data in SELECT-PsA 2 trial

AbbVie discovered and developed Rinvoq, a selective and reversible inhibitor of JAK. Credit: AbbVie Inc.



  • AbbVie’s Rinvoq yields positive data in SELECT-PsA 2 trial